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Abstract
Purpose This systematic review determines the best known
form of biofeedback (BF) and/or electrical stimulation (ES)
for the treatment of fecal incontinence in adults and rates the
quality of evidence using the Grades of Recommendation,
Assessment, Development, and Evaluation. Attention is giv-
en to type, strength, and application mode of the current for
ES and to safety.
Methods Methods followed the Cochrane Handbook. Ran-
domized controlled trials were included. Studies were
searched in The Cochrane Library, MEDLINE, and EMBASE
(registration number (PROSPERO): CRD42011001334).
Results BF and/or ES were studied in 13 randomized parallel-
group trials. In 12 trials, at least one therapy group received
BF alone and/or in combination with ES, while ES alone was
evaluated in seven trials. Three (four) trials were rated as of
high (moderate) quality. Average current strength was report-
ed in three of seven studies investigating ES; only two studies
reached the therapeutic window. No trial showed superiority
of control, or of BF alone or of ES alone when compared with
BF + ES. Superiority of BF + ES over any monotherapy was
demonstrated in several trials. Amplitude-modulatedmedium-
frequency (AM-MF) stimulation, also termed pre-modulated
interferential stimulation, combined with BF was superior to
both low-frequency ES and BF alone, and 50% of the patients
were continent after 6 months of treatment. Effects increased
with treatment duration. Safety reporting was bad, and there
are safety issues with some forms of low-frequency ES.
Conclusions There is sufficient evidence for the efficacy of
BF plus ES combined in treating fecal incontinence. AM-MF
plus BF seems to be the most effective and safe treatment.
Key Messages
• The higher the quality of the randomized trial the more likely
was a significant difference between treatment groups.
• Two times more patients became continent when biofeed-
back was used instead of a control, such as pelvic floor
exercises.
• Two times more patients became continent when biofeed-
back plus electrical stimulation was used instead of bio-
feedback only.
• Low-frequency electrical stimulation can have adverse
device effects, and this is in contrast to amplitude-
modulated medium-frequency electrical stimulation.
• There is high quality evidence that amplitude-modulated
medium-frequency electrical stimulation plus electromyog-
raphy biofeedback is the best second-line treatment for
fecal incontinence.
Keywords Conservative treatment . Biofeedback .
Cleveland Clinic score . Electrical stimulation .
Fecal incontinence . Meta-analysis
Abbreviations
ADE Adverse device effect
AM-MF Amplitude-modulated
medium-frequency stimulation
Electronic supplementary material The online version of this article
(doi:10.1007/s00384-013-1739-0) contains supplementary material,
which is available to authorized users.
R. Vonthein :A. Ziegler (*)
Institut für Medizinische Biometrie und Statistik, Universität zu
Lübeck, Universitätsklinikum Schleswig-Holstein, Campus
Lübeck, Ratzeburger Allee 160, Haus 24, 23562 Lübeck, Germany
e-mail: ziegler@imbs.uni-luebeck.de
R. Vonthein :A. Ziegler
Zentrum für Klinische Studien Lübeck, Universität zu Lübeck,
Lübeck, Germany
T. Heimerl : T. Schwandner
Klinik für Allgemein-, Viszeral-, Thorax-, Transplantations- und
Kinderchirurgie, Zentrum für minimalinvasive Chirurgie,
Universitätsklinikum Gießen und Marburg GmbH, Standort
Gießen, Gießen, Germany
Int J Colorectal Dis (2013) 28:1567–1577
DOI 10.1007/s00384-013-1739-0
ANOVA analysis of variance
BF Biofeedback




FIQoL Fecal incontinence quality
of life
LFS Low-frequency stimulation
PFE Pelvic floor exercises
QoL Quality of life
RCT Randomized controlled trial
RR Relativ risk
SAE Serious adverse event
Introduction
Approximately 1 % of adults suffer from uncontrolled loss of
stool [1, 2]. Very few guidelines for managing fecal inconti-
nence in adults are available, and one of these was issued by
the National Institute for Health and Clinical Excellence for
UK in 2007 [3]. In general, the first-line therapy may try to
solidify liquid stools with fiber elements or medications [4].
The specialized management usually applies nonsurgical
methods, such as pelvic floor exercises (PFE), biofeedback
(BF), and electrical stimulation (ES) [3], to improve the
strength and coordination of the sphincter muscles.
However, the internal anal sphincter consists of smooth
muscles and is not amenable to voluntary exercises. Further-
more, it is difficult to actively reach the slow-twitch type I
fibers [5, 6]. It thus makes sense to use ES on the smooth and
slow muscular components.
When judging the efficacy of the ES treatment or the
combination of BF and ES (BF + ES), current type, current
strength, and application mode are essential [6–10], as re-
cently discussed by Schwandner et al. [11].
For example, Telford and colleagues [5] demonstrated
that the motorical threshold for sphincter muscles with low-
frequency electrical stimulation (LFS) is around 20 mA.
Specifically, they used the strength-duration test to measure
the current strength required for visible muscle contraction at
different pulse durations. They first found that the current
intensity at 1 ms pulse duration was the best predictor of
incontinence [5]. Furthermore, in their control group [12],
they observed that a currency of 18.2 mA (90 % reference
interval ≥19 mA) was required at 1 ms pulse duration for
muscle contraction.
LFS, as used in most studies of fecal incontinence, can be
very painful when applied to the pelvic floor exercises
[13–15], and it can cause adverse device effects (ADE) [13].
Surprisingly, this relationship between pulse configuration,
voltage amplitudes, and physiological outcome has not been
addressed in any of the systematic reviews on ES for fecal
incontinence, although it is well known in biomedical engi-
neering [6–10]. It was also neglected in some two-group
randomized trials where two ES stimulations were compared
and both ES were below the threshold for effectiveness [13].
Stimulation with alternating current at medium frequency
(MF>1,000 Hz; amplitude-modulated medium frequency:
AM-MF), also termed pre-modulated interferential ES in the
literature, does not have the disadvantage of LFS because its
biological effect is based on a different principle than the all-
or-nothing effect of LFS [16]. Previous systematic reviews
[Supplementary Table S1; 17–19] did not distinguish between
LFS and MF therapies.
The systematic reviews focused either on ES [17] or on
BF [18, 19], but they did not consider ES + BF to be a
combination therapy which would be important for treatment
guidelines. Here, we aim at identifying the best second-line
conservative treatment, consisting in BF, ES, or BF + ES by
taking into account the type, strength, and application mode
of current. We specifically address duration–response rela-
tionships which were not correctly reported in previous re-
views [19] and safety issues. By finally grading the evidence
[20], we provide valuable aid to decision making in a guide-
line for fecal incontinence.
Methods
The protocol to this systematic review was published in PROS-
PERO (CRD42011001334) on June 1, 2011. A detailed de-
scription of the methods can be found in the Electronic
supplementary material. In brief, we included randomized con-
trolled parallel-group trials of BF or ES or BF + ES in adults in
need of a second-line conservative treatment and no obvious
need for surgery for fecal incontinence reporting patient-related
outcome, i.e., remission, response, or disease-related quality of
life (QoL) on validated scales as assessed by two reviewers in
consensus. Data extraction followed recommendations of the
Cochrane Handbook for Systematic Reviews of Intervention
[21]; for details, see Electronic supplementary material.
Excluded studies and reasons for exclusion are summa-
rized in Supplementary Table S2. Supplementary Tables S3
and S4 provide details on populations, interventions, com-
parator, outcome, and design of included studies to find
matching entries for meta-analysis. Safety issues were coded
as serious adverse events (SAE) and adverse device effects
(ADE), both according to ISO 14155:2011.
The 2×2 treatment scheme has been analyzed using an
analysis of variance meta-analysis (meta-ANOVA) [22] for
the endpoint remission using the relative risk (RR) as effect
measure. Results were graded high, moderate, or low quality
using the Grades of Recommendation, Assessment, Devel-
opment, and Evaluation (GRADE) [20].
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Results
Study selection
We identified 128 potentially relevant studies from titles and
abstracts (Supplementary Fig. S1), including several system-
atic reviews (Supplementary Table S1) [4, 17, 19, 23–36].
Twenty-three studies were retrospective chart reviews or
prospective case series [37–59], and four current trials
[60–63] were found in trial registries, but not in the literature.
Seven RCTs [15, 64–69] met at least one exclusion criterion
(Supplementary Table S2), and 13 RCTs remained [11, 14,
16, 18, 70–78] (Supplementary Tables S3 to S5).
Qualitative summary
We identified two different groups of patients in the RCTs.
The first group of studies predominantly included younger
mothers [70, 73, 74], but females only [16, 75], and the
second group included patients of all ages (predominantly
elderly) and both sexes (predominantly women) [11, 14, 16,
71, 72, 76–78]; Supplementary Text 2 of the Electronic
supplementary material. In one of the 13 RCTs [78], the
active ES treatment and the active ES placebo had 2.3 and
0.13 mA current and were substantially below the therapeu-
tic window of about 20 mA [5].
The quality of the RCTs varied substantially (Supplemen-
tary Table S3), and Fig. 1 shows that there was a strong
correlation between trial quality and group size (r=0.81;
p=0.0007). Furthermore, significant trials tended to be of
better quality (one-sided, p=0.0299) and to have a larger
group size (one-sided, p=0.0450).
Only three of the 13 trials [11, 72, 77] fulfilled all quality
criteria; the other trials may have incurred biases. For exam-
ple, intention-to-treat (ITT) analyses were performed in the
absence of a validated outcome measure or a masked asses-
sor in some trials [14, 18, 73, 78], and these studies were
considered as moderate quality evidence. Good and moder-
ate quality studies reported adequate randomization proce-
dures and case number determinations. Other trials [16, 70,
71, 74–76] were considered as low quality. Several reasons
lead to a downgrading of these trials. For example, the RCT
by Heymen [76] was lacking of a validated score, it had a
large variability due to small sample size, and 20 % of the
patients were missing in three of four groups. Figure 2 sum-
marizes treatments and effects after exclusion of low-quality
trials and trials with too low current; see Supplementary
Fig. S2 for all trials. Figure S3 displays effect sizes and
95 % confidence intervals (CI) for all trials. First, no trial
showed superiority of control. Second, no trial showed su-
periority of any monotherapy, when compared with BF + ES.
The longer and more intensive the treatment the stronger
were the effects (Supplementary Tables S4 and S5). This
finding holds both within and across trials.
Quantitative data summary
For meta-analysis, we chose the remission rate because it
was the endpoint with the greatest patient relevance, and it
was the most completely reported endpoint. Results were
similar for other endpoints (Cleveland Clinic score (CCS):
Table 1; z scores for any validated outcome: Supplementary
Table S5).
The meta-ANOVA of at least medium-quality trials
showed the tendency for inferiority for ES when compared
with (RR=0.47; 95%CI, 0.13–1.72; p=0.25) and superiority
of BF over control (RR=2.35; 95% CI, 1.33–4.16;
p=0.0033) (Table 2). The combination therapy BF+ES
was superior to both BF (RR=2.12; 95% CI, 1.42–3.16;
p=0.00022) and ES (RR=22.97; 95% CI, 1.81–291.69;
p=0.016) (Table 2). No positive results on ES versus BF or
control emerged. RRs for BF over control and for ES on top
of BF over BF were close to 2 when all trials were included,
when adjustments were made for treatment duration or du-
ration of continence.
When AM-MF ES was considered to be a different therapy
concept from LFS, similar results were obtained (Supplemen-
tary Table S6). Specifically, both LFS and the combination of
LFS and BF were not superior to not doing these therapies
(p=0.96 and p=0.49), while BF alone and the combination of
AM-MF + ES were superior to not doing these therapies
(p=0.005 and p=0.002; Supplementary Table S6).
EMG-BF plus AM-MF ES sent 42 and 54 % of patients
into remission [11, 72], 75 % of patients were asymptomatic
with the combination of BF and LFS in [73], 27 %
Fig. 1 Quality of trials by sample size per group. Full and open circles
display randomized controlled trials with and without significant dif-
ferences between treatment groups, respectively. There is a clear corre-
lation between group size and quality of trials. Significant trials tend to
be of better quality (one-sided, p=0.0299) and tend to have a larger
group size (one-sided, p=0.0450)
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completely asymptomatic in [74], and no patient cured in
[16]. Different modes of BF brought between 20 and 54 %
remissions [72, 73, 75, 76]. LFS yielded the worst remission
rates which varied between 0 and 4 % [11, 16, 70, 78].
Safety
Reporting of adverse events was patchy, not in accordance with
definitions [71], and SAEs were reported in the text or in flow
charts of only three trials: 2 in 15 patient years of insufficient or
sham ES [78], 5 in 64 patient years of BF or control [18], 8 in
59 patient years of EMG-BF plus AM-MF ES, and 5 in 59
patient years of EMG-triggered stimulation [72]. This indicates
homogeneous populations with 0.15 disruptive SAE per patient
year. ADEs that led to treatment discontinuation were reported
for a total of 31 cases (5.6 %) in seven trials with 728 partic-
ipants [11, 14, 18, 71, 72, 78, 79] and in one description of low-
frequency ES [13]. Nondisruptive ADEs were reported in one
trial [11], the persisting pain is close to half of patients using
LFS and none using AM-MF stimulation.
Grading the quality of evidence
The number of patients in remission is considered to be a valid
and patient-relevant endpoint as are validated incontinence
scores when masked observers are used and when data are
analyzed on an ITT basis. However, the definition of remis-
sion differed across trials. It was described as asymptomatic
[73], completely asymptomatic [74], best possible effect on a
10-point scale [70], no accident in 1 week [14, 18, 75, 76], a
score of 0 in an incontinence scale when asked about the last
30 days [11, 71, 72], and cured [16, 18, 78]. The different
definitions had an effect on the proportion of missing data
which was as large as 39 % because of the incompleteness of
patient diaries [18].
One aspect for grading quality of trials is duration-response
gradients. Two trials reported assessments in 3-month inter-
vals, and a duration-response gradient could be observed [80].
Specifically, the longer the treatment the more patients were in
remission and scored better treatment response.
Risk of bias across studies
There are two obvious sources of heterogeneity between
studies. First, the spectrum of patients included in the trials
was diverse. Trials in predominantly younger mothers can-
not be compared with trials in elderly patients of both sexes
despite of the different etiology in these patients. And there
are other inclusion/exclusion factors which might be prog-
nostic for treatment effect. Anatomic defect or inflammatory
Fig. 2 Results and quality of clinical trials, with at least moderate quality
of biofeedback (BF), sufficient electrical stimulation (ES), or biofeedback
plus electrical stimulation (BF + ES). A triangle denotes significant differ-
ence between two stimulation modes; a bar represents not statistically
significant difference. Trial quality is color coded: moderate, high.
Size of bars or triangles is proportional to case numbers ranging from 40
[73] to 171 [18]. For example, the trial by Heymen and colleagues [14] is of
moderate quality, demonstrated superiority of BF over PFE alone, and a
total of 108 patients were randomized in the trial. The off-diagonals
represent the twomonotherapies, the top left represents control and includes
pelvic floor exercises (PFE) or some other standard therapywhich is neither
BF nor ES. The bottom right represents the combination therapy BF + ES
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chronic bowel disease was an explicit exclusion criterion in
some studies [77], while these patients were included in other
trials [14]. Previous anorectal surgery and anal sphincter dam-
age were classified differently across studies, and the extent of
heterogeneity remained unclear after data extraction.
Second, the treatment forms varied substantially (Supple-
mentary Table S4), and the most important differences were
type of treatment, patient position, and intensity of first- and
second-line treatment. ES studies differed in treatment dura-
tion and average current which sometimes was even below
the treatment window.
Six included trials were found in public registries [81–86].
Selection or publication biases were not apparent. Registra-
tion information and consistency between information in the
registry and the published report needs improvement.
Table 1 Remission rate (in %) and duration and response (change in Cleveland Clinic score) by treatment group and trial quality for control,
biofeedback, electrical stimulation, and combination of BF and ES
Remission CCS Quality Treatment Cases Trial
[%] Duration change
54 1 month −7 high AM-MF ES + BF (EMG) 40 Schwandner 2011 [72]
42 1 month −8 high AM-MF ES + BF (EMG) 79 Schwandner 2010 [11]
75 – – moderate LFS + BF (EMG) + PFE 20♀ Fynes 1999 [73]
27 – −2 low LFS + BF (EMG) + PFE 30♀ Mahony 2004 [74]
0 – −5.5 low LFS + BF (EMG) 24 Healy 2006 [16]
20 1 month −5 high BF (EMG) 79 Schwandner 2010 [11]
8 | 39 cured | 1 week – moderate BF (EMG) + PFE + Edu 42 Norton 2003 [18]
4 | 39 cured | 1 week – moderate BF (balloon) + PFE + Edu 49 Norton 2003 [18]
44 1 week – moderate BF (balloon) + PFE + Edu 45 Heymen 2009 [14]
35 – – moderate BF (balloon) + PFE 20♀ Fynes 1999 [73]
19 1 month −6.5 low BF (balloon) + PFE 72 Bartlett 2011 [71]
54 1 week – low BF (balloon) + Edu 11♀ Ilnyckyj 2005 [75]
≥40 1 week – low BF (EMG) + ST + Edu 10 Heymen 2000 [76]
≥20 1 week – low BF (EMG) + Edu 10 Heymen 2000 [76]
≥20 1 week – low BF (EMG) + ST + Edu 10 Heymen 2000 [76]
20 1 week – low BF (EMG) + Edu 10 Heymen 2000 [76]
20 – −2 low BF (EMG) + PFE 30♀ Mahony 2004 [74]
4 – −1 low BF (EMG) 24♀ Naimy 2007 [70]
0 | 39 cured | 1 week – moderate PFE + Edu 43 Norton 2003 [18]
0 | 39 cured | 1 week – moderate Edu 37 Norton 2003 [18]
0 cured – moderate LFS (Sham) + PFE 43 Norton 2005 [78]
21 1 week – moderate PFE + Edu 63 Heymen 2009 [14]
41 1 week – low Edu 12♀ Ilnyckyj 2005 [75]
0 1 month +1 high LFS 40 Schwandner 2011 [72]
2 cured – moderate LFS + PFE 47 Norton 2005 [78]
4 – −4.8 low LFS 24 Healy 2006 [16]
0 – −1 low LFS 25♀ Naimy 2007 [70]
AM-MF ES amplitude-modulated medium-frequency stimulation, + plus, BF biofeedback, EMG electromyography, – not reported, LFS low-
frequency electrical stimulation, PFE pelvic floor exercises, ♀ recent mothers, Edu education, ST sensory training, BF biofeedback, ES electrical
stimulation, ES + BF combination of BF and ES
Table 2 Meta-analysis results from two-way analysis of variance for
remission for all trials of at least moderate quality. Electrical stimulation
tended to be inferior to control, while biofeedback was superior to
control. The combination therapy BF + ES was superior to both
monotherapies
Comparison RR 95 % CI p
ES vs. control 0.47 0.13–1.72 0.25
BF vs. control 2.35 1.33–4.16 0.0033
BF + ES vs. BF 2.12 1.42–3.16 0.00022
BF + ES vs. ES 22.97 1.81–291.69 0.016
Heterogeneity τ2 <0.0001 (95% CI: 0.00–0.25; p=0.4830). The meta-
analysis included six trials: [71, 76] compared only two modes of BF;
[77] did not report data on remission.
RR relative risk, CI confidence interval, ES Electrical stimulation, BF
biofeedback
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Specifically, in four trials, there was no information or in-
consistent information on primary and secondary outcomes.
The primary endpoint was altered in two trials [14, 72], in
both trials for very good reasons.
Discussion
Following up on promising results of the combination of ES
with BF, this systematic review revealed more, high-quality
evidence than previous reviews because of the publication of
several new trials [11, 14–16, 70–72, 87]. The clinical de-
velopment of BF and ES can be grouped into three general
phases. In the first phase, diverse case series were reported,
and those had to be excluded from this systematic review.
In the second phase, narrow patient populations were
studied. Specifically, fecal incontinence in younger females
after delivery was considered in several trials [70, 73–75].
Outcome measures included patient diary and manometry.
While manometry does not adequately reflect treatment re-
sponse [16], diaries were incomplete with missing data as
high as 39 % [18]. To avoid missing data in questionnaires,
patients are nowadays asked about continence/incontinence
in the recent past, such as the preceding week or month.
In the third phase, several RCTs studied the intensity,
duration, and the mode of BF and ES treatments. BF was
given optically or acoustically, signaling change in pressure,
in electromyogram (EMG) or ultrasound. EMG devices for
home use were developed so that daily sessions at home were
added to sessions with a therapist. ES used different frequen-
cies and current strengths. Such “dose finding” sometimes
required more than two treatment groups. The studies tended
to be small so that not all comparisons were significant. The
combination BF + ES was studied in recent RCTs of higher
quality, which included sufficiently large numbers of patients,
investigated several patient relevant endpoints at the final
follow-up and also reported changes over time.
Two high-quality RCTs showed a consistently efficacious
combination of AM-MF ES plus EMG-BF with 50 % patients
being continent after 6 or 9 months of treatment. This treatment
was consistently superior to low-frequency ES and to BF alone.
Two important aspects need to be addressed in future
studies on fecal incontinence. First, an in-depth discussion
on primary patient-relevant endpoint to be used is required.
Specifically, Norton [88] argued that QoL should be the
primary outcome. We do not agree with her conclusion. If
the aim is to treat patients suffering from fecal incontinence, a
successful treatment needs to make a patient continent. The
degree of incontinence measured using a validated score, such
as the CCS is semiquantitative and requires fewer study
subjects than the dichotomous continent/incontinent endpoint.
However, it is difficult to measure continence reliably because
of different patient perceptions.
QoL is an important patient-related endpoint. If QoL is
assessed in an elderly population suffering from fecal inconti-
nence, the constructs determining their QoL need to be assessed
reliably. For example, the fecal incontinence QoL questionnaire
enquires sexual activities, traveling by plane or train, or eating
out [89]. Patients seen in our own studies stated that these
activities were not determining their QoL. The most important
restrictions for their life was the personal stress caused by fecal
incontinence, an important aspect was that whatever they did,
the toilet had to be within reach [90]. There is a clear need for
developing a reliable and valid QoL instrument for an elderly
population suffering from fecal incontinence.
Remissions and responses were more frequent the longer
the therapy lasted. This was demonstrated within two trials
of highest quality and across trials. In consequence, both
individual results and the synthesis could be graded higher.
In their recent systematic review, Norton and Cody [19]
stated “No study reported any adverse events or deterioration
in symptoms, …”. According to this systematic review, this
statement needs to be corrected. Although reporting of safety
was scarce, there were trials with SAEs, such as mortality,
and even ADEs were reported in seven of 13 trials. Deteri-
oration of symptoms was commonly reported as mean
changes with standard deviations indicating a considerable
proportion of changes for the worse. Specifically, [11] ex-
plicitly reported deterioration in 10.3 % under AM-MF ES
plus EMG-BF and 82.9 % for LFS.
In their systematic review, Hosker and colleagues [17] stated
that “electrical stimulation can cause a tissue reaction at the site
of the electrodes. This usually resolves speedily when stimula-
tion is stopped.” This statement is in line with the findings of
[11] who reported that approximately half of the patients re-
ceiving LFS treatment complained of pain during stimulation,
and a quarter could not tolerate high currents required to reach
the motor threshold. Some patients reported a feeling of pres-
sure that persisted for hours after training. But these side effects
in the trial were only minor ones due to thorough precautions
which are not taken for granted in daily practice.
In separate work, we showed [13] that ADEs can occur with
some devices. A major concern is the danger of tissue damage
at the electrode/tissue interface. This is described in detail in
the Supplementary Text 3 of the Electronic supplementary
material.
Using the GRADE approach, we graded the quality of the
trials and summarized the evidence (Table 3). In their recent
review, Norton and Cody [19] stated that “treatment options
for fecal incontinence have not yet been investigated bymeans
of well-designed trials.” The result of our systematic review is
different. We have identified three well-designed randomized
controlled trials of high quality [11, 72, 77] and another three
trials of medium quality and sufficient ES [14, 18, 73].
One limitation of this review is that observational
studies were excluded. Such quasi-randomized studies





























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Int J Colorectal Dis (2013) 28:1567–1577 1573
were considered as evidence of safe treatments involving
properly working devices rather than evidence of efficacy.
Furthermore, trial registries did not cover all trials before the
2008 version of the Declaration of Helsinki.
Despite these limitations, this systematic review is the
first considering BF and ES to be a combination therapy,
and in a supplementary analysis LFS was distinguished from
AM-MF ES. An overview of the component treatments, their
respective duration and intensity gradients is provided. End-
points were weighted by grade of evidence to embed and
support the results of pivotal trials. A first survey of safety is
provided and discussed.
Conclusions
This systematic review demonstrated a superiority of BF over
control and of the combination therapy BF + ES over BF and
ES monotherapies. These findings were stable in sensitivity
analyses. It was additionally found that LFS did not have a
positive effect, either alone or in combination with BF. Both
BF alone and AM-MF plus BF were superior to not doing
these therapies. LFS has a risk for pain and a device-specific
risk for tissue damage. There is sufficient evidence of high
quality for a stronger recommendation for a certain treatment
regimen of BF, ES, or BF + ES to patients with fecal incon-
tinence. Specifically, we conclude that the combination of
AM-MF ES in an EMG-triggered application mode plus
EMG-BF should gain a stronger recommendation as special-
ized management. BF deserves a weaker recommendation.
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Box
Fecal incontinence
The anus is closed by the voluntary outer and the involuntary
inner sphincter and the anal columns. Little pressure rests on
these, as the rectum is folded by the voluntary musculus
puborectalis. The muscles contract reflexively whenever
pudendal and sacral nerves signal pressure. As continence
is learned by toddlers, it can be forgotten and retrained. More
common causes of fecal incontinence are damages to the
muscles involved, particularly during delivery, or
weaknesses of other parts involved, like rectocele,
hemorrhoids, and prolapse.
Biofeedback
Biofeedback in a wider sense of a training aided by a real-
time signal of proper functioning has been studied for
decades. Pelvic floor exercises were augmented by such
control. This facilitates the selective training of muscles
one rarely contracts at will and does not discern during the
normal defecation reflex.
Balloon manometers, electromyographs, ultrasound
devices, and fingertips have been used as sensors. Signals
are displayed usually on a screen or a line of light emitting
diodes but may be given acoustically. Signal amplification
needs to be adjustable to individual anatomy, conductivity
and muscle strength at the time being.
When manometry studies are used to recalibrate the
sensors of the rectum, this is sensory training and does not
figure as biofeedback in this systematic review.
Electrical stimulation
Transcutaneous electrical stimulation (ES) comprises of
pulses that trigger action potentials controlling muscle con-
traction. Contraction is sustained by perhaps 20 to 120 action
potentials per second (Hz). Pulses of that frequency are
applied for some seconds at a time with some seconds rest
in between. Regular training can lead to a buildup of
muscle mass. A good anal electrode can reach both
sphincters and the puborectalis muscle. The electrical
current needs to be adjustable to electrical conductivity
and pain tolerance. Unfortunately, pain sensors are stimu-
lated too. They respond to the same low-frequency pulses.
So, patients often do not tolerate currents high enough for
muscle contraction.
AM-MF ES (1 kHz to 1 MHz) elicits low-frequency
action potentials, less pain and more natural muscle con-
tractions [11].
EMG-triggered ES connects biofeedback to ES and is
thought to condition proprioceptive motor control even
before muscle buildup [11].
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